Return to homepagePandemic Pact

Testing plasma from recovered COVID-19 patients as a possible treatment

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Principal Investigator

    Dr and Dr Alan and Dean Tinmouth and Fergusson

  • Research Location

    Canada

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Children (1 year to 12 years)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Drs. Alan Tinmouth and Dean Fergusson are contributing to the global effort to determine if plasma from people who have recovered from COVID-19 (called convalescent plasma) could be an effective treatment for actively infected patients. When someone becomes infected with COVID-19, their immune system develops antibodies against the virus. After they have recovered, these antibodies remain present in their plasma to shield them from possible future infection. In theory, these antibodies could be transfused into people with an active COVID-19 infection, to help them fight off the virus. The trial will be conducted by the Canadian Transfusion Research Network in collaboration with Canadian Blood Services and Hema-Québec who will collect and test convalescent plasma in adults (CONCOR-1 study) and children (CONCOR-Kids study).